VivoSeq
Metabolic & Endocrine

Type 1 Diabetes

302

Pipeline Programs↗

104

Active Trials↗

92

Companies Involved↗

Type 1 Diabetes is a highly competitive landscape with 302 programs across 92 companies. The most active players are Gan and Lee Pharmaceuticals, USA, Carmot Therapeutics, Inc., Rise Therapeutics LLC. 33 therapies are approved with 46 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

88/100

Pipeline Velocity

58/100

Mech. Concentration

4/100

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gan and Lee Pharmaceuticals, USA

2 programs

Phase 1C

Carmot Therapeutics, Inc.

1 program

Phase 1R

Rise Therapeutics LLC

1 program

Phase 1M

Maastricht Radiation Oncology

1 program

Phase 1F

Fate Therapeutics

1 program

Phase 1N

Nastech Pharmaceutical Company, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

87%

Small molecule

287 of 331 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody196%Peptide124%Protein / enzyme62%Cell therapy41%Vaccine3<1%

Small molecule leads; the ring shows all 331 classified programs, each share of the total. Modality classified for 99% of 385 pipeline programs.

Analysis

Trial Status

579

clinical trials

Completed391 · 68%
Recruiting59 · 10%
Unknown status32 · 6%
Terminated28 · 5%
Active, not recruiting26 · 4%
Withdrawn21 · 4%
Other22 · 4%

Clinical Trials

Trial Activity

579 trials

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
Recruiting·MMedical University of South Carolina·Phase 1·NCT04061746·60 enrolled
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Recruiting·UUniversity of Washington·Phase 2·NCT05822609·60 enrolled
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Recruiting·ZZucara Therapeutics Inc.·Phase 2·NCT05762107·186 enrolled
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Recruiting·—·Phase 1·NCT04449198·24 enrolled
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
Recruiting·YYale University·Phase 1·NCT06105931·15 enrolled
Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes
Recruiting·UUniversity of Virginia·Phase 2·NCT07186660·40 enrolled
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
Recruiting·UUniversity of Bern·Phase 3·NCT06630585·42 enrolled
Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes
Recruiting·MMedical University of Lodz·Phase 2·NCT05957055·150 enrolled
UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes
Recruiting·SShanghai Changzheng Hospital·N/A·NCT06407297·24 enrolled
Characterization of Autoreactive Regulatory and Conventional CD4 T Cells in Recent Onset Type 1 Diabetes and Control Individuals
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT06427421·80 enrolled
Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes
Recruiting·IInstitut de Recherches Cliniques de Montreal·N/A·NCT05258292·86 enrolled
INfluenza VaccInation To Mitigate typE 1 Diabetes
Recruiting·—·Phase 4·NCT05585983·100 enrolled
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States
Recruiting·Sanofi logoSanofi·N/A·NCT07260110·550 enrolled
Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab
Recruiting·PPirogov Russian National Research Medical University·Phase 2·NCT07041268·116 enrolled
A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT07305805·36 enrolled
Page 1 of 39

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)